Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors

Bibliography

• Rosenberg SA. Cell transfer immunotherapy for metastatic solid cancer–what clinicians need to know. Nat Rev Clin Oncol 2011;8(10):577-85
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 1991;174(1):139-49
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994;153(4):1687-96
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Mehta BA, Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993;21(13):1673-9
   PubMed Web of Science ®Google Scholar
• Franceschetti M, Pievani A, Borleri G, Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp Hematol 2009;37(5):616-28; e2
   PubMed Web of Science ®Google Scholar
• Hayes MP, Wang J, Norcross MA. Regulation of interleukin-12 expression in human monocytes: selective priming by interferon-gamma of lipopolysaccharide-inducible p35 and p40 genes. Blood 1995;86(2):646-50
   PubMed Web of Science ®Google Scholar
• Ma X, Chow JM, Gri G, The interleukin 12 p40 gene promoter is primed by interferon gamma in monocytic cells. J Exp Med 1996;183(1):147-57
   PubMed Web of Science ®Google Scholar
• Lopez RD, Waller EK, Lu PH, Negrin RS. CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells. Cancer Immunol Immunother 2001;49(12):629-40
   PubMed Web of Science ®Google Scholar
• Ochoa AC, Gromo G, Alter BJ, Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. J Immunol 1987;138(8):2728-33
   PubMed Web of Science ®Google Scholar
• Anderson PM, Bach FH, Ochoa AC. Augmentation of cell number and LAK activity in peripheral blood mononuclear cells activated with anti-CD3 and interleukin-2. Preliminary results in children with acute lymphocytic leukemia and neuroblastoma. Cancer Immunol Immunother 1988;27(1):82-8
   PubMed Web of Science ®Google Scholar
• Leemhuis T, Wells S, Scheffold C, A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005;11(3):181-7
   PubMed Web of Science ®Google Scholar
• Baker J, Verneris MR, Ito M, Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 2001;97(10):2923-31
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Martinuzzi E, Todorovic M, Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implications for their infusion across major HLA barriers. Int Immunol 2008;20(7):841-8
   PubMed Web of Science ®Google Scholar
• Zoll B, Lefterova P, Csipai M, Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12. Cancer Immunol Immunother 1998;47(4):221-6
   PubMed Web of Science ®Google Scholar
• Bonanno G, Iudicone P, Mariotti A, Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokine-induced killer (CIK) cells in clinical-grade cultures. J Transl Med 2010;8:129
   PubMed Web of Science ®Google Scholar
• Rettinger E, Kuci S, Naumann I, The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2011;14(1):91-103
   PubMed Web of Science ®Google Scholar
• Li H, Yu JP, Cao S, CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. J Clin Immunol 2007;27(3):317-26
   PubMed Web of Science ®Google Scholar
• Todorovic M, Mesiano G, Gammaitoni L, Ex-vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across MHC-barriers. EHA; 2011
   Google Scholar
• Introna M, Franceschetti M, Ciocca A, Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006;38(9):621-7
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007;92(7):952-9
   PubMed Web of Science ®Google Scholar
• Alvarnas JC, Linn YC, Hope EG, Negrin RS. Expansion of cytotoxic CD3+ CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant 2001;7(4):216-22
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011;118(12):3301-10
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau SK, Liu BH, Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology 2008;126(3):423-35
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Johnston V, Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 1994;87(3):453-8
   PubMed Web of Science ®Google Scholar
• Karimi M, Cao TM, Baker JA, Silencing human NKG2D, DAP10, and DAP12 reduces cytotoxicity of activated CD8+ T cells and NK cells. J Immunol 2005;175(12):7819-28
   PubMed Web of Science ®Google Scholar
• Verneris MR, Karami M, Baker J, Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood 2004;103(8):3065-72
   PubMed Web of Science ®Google Scholar
• Jamieson AM, Diefenbach A, McMahon CW, The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17(1):19-29
   PubMed Web of Science ®Google Scholar
• Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med 1991;173(4):1017-20
   PubMed Web of Science ®Google Scholar
• Diefenbach A, Jamieson AM, Liu SD, Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1(2):119-26
   PubMed Web of Science ®Google Scholar
• Cosman D, Mullberg J, Sutherland CL, ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14(2):123-33
   PubMed Web of Science ®Google Scholar
• Groh V, Rhinehart R, Secrist H, Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96(12):6879-84
   PubMed Web of Science ®Google Scholar
• Verneris MR, Ito M, Baker J, Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma. Biol Blood Marrow Transplant 2001;7(10):532-42
   PubMed Web of Science ®Google Scholar
• Laport GG, Sheehan K, Baker J, adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17(11):1679-87
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Lefterova P, Johnston V, Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cell Immunol 1996;169(1):85-90
   PubMed Web of Science ®Google Scholar
• Margolin KA, Negrin RS, Wong KK, Cellular immunotherapy and autologous transplantation for hematologic malignancy. Immunol Rev 1997;157:231-40
   PubMed Web of Science ®Google Scholar
• Hoyle C, Bangs CD, Chang P, Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 1998;92(9):3318-27
   PubMed Web of Science ®Google Scholar
• Finke S, Trojaneck B, Lefterova P, Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3+ CD56+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene. Gene Ther 1998;5(1):31-9
   PubMed Web of Science ®Google Scholar
• Nagaraj S, Ziske C, Schmidt-Wolf IG. Human cytokine-induced killer cells have enhanced in vitro cytolytic activity via non-viral interleukin-2 gene transfer. Genet Vaccines Ther 2004;2(1):12
   PubMedGoogle Scholar
• Hongeng S, Petvises S, Worapongpaiboon S, Generation of CD3+ CD56+ cytokine-induced killer cells and their in vitro cytotoxicity against pediatric cancer cells. Int J Hematol 2003;77(2):175-9
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Sangsuriyong S, Hongeng S, Effective osteosarcoma cytolysis using cytokine-induced killer cells pre-inoculated with tumor RNA-pulsed dendritic cells. J Orthop Res 2005;23(6):1460-6
   PubMed Web of Science ®Google Scholar
• Kuci S, Rettinger E, Voss B, Efficient lysis of rhabdomyosarcoma cells by cytokine-induced killer cells: implications for adoptive immunotherapy after allogeneic stem cell transplantation. Haematologica 2010;95(9):1579-86
   PubMed Web of Science ®Google Scholar
• Basse P, Herberman RB, Nannmark U, Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 1991;174(2):479-88
   PubMed Web of Science ®Google Scholar
• Wongkajornsilp A, Somchitprasert T, Butraporn R, Human cytokine-induced killer cells specifically infiltrated and retarded the growth of the inoculated human cholangiocarcinoma cells in SCID mice. Cancer Invest 2009;27(2):140-8
   PubMed Web of Science ®Google Scholar
• Sangiolo D, Mesiano G, Cammarata C, Effective preclinical adoptive immunotherapy with cytokine-induced killer cells for bone sarcomas. EBMT; 2011. Bone Marrow Transplantation 2011;46:87
   Google Scholar
• Kim HM, Kang JS, Lim J, Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch Pharm Res 2009;32(5):781-7
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim J, Kang JS, Inhibition of human cervical carcinoma growth by cytokine-induced killer cells in nude mouse xenograft model. Int Immunopharmacol 2009;9(3):375-80
   PubMed Web of Science ®Google Scholar
• Chan JK, Hamilton CA, Cheung MK, Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res 2006;12(6):1859-67
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim J, Park SK, Antitumor activity of cytokine-induced killer cells against human lung cancer. Int Immunopharmacol 2007;7(13):1802-7
   PubMed Web of Science ®Google Scholar
• Kim HM, Lim J, Yoon YD, Anti-tumor activity of ex vivo expanded cytokine-induced killer cells against human hepatocellular carcinoma. Int Immunopharmacol 2007;7(13):1793-801
   PubMed Web of Science ®Google Scholar
• Kim HM, Kang JS, Lim J, Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch Pharm Res 2007;30(11):1464-70
   PubMed Web of Science ®Google Scholar
• Sweeney TJ, Mailander V, Tucker AA, Visualizing the kinetics of tumor-cell clearance in living animals. Proc Natl Acad Sci USA 1999;96(21):12044-9
   PubMed Web of Science ®Google Scholar
• Nishimura R, Baker J, Beilhack A, In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity. Blood 2008;112(6):2563-74
   PubMed Web of Science ®Google Scholar
• Schmidt-Wolf IG, Finke S, Trojaneck B, Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 1999;81(6):1009-16
   PubMed Web of Science ®Google Scholar
• Olioso P, Giancola R, Di Riti M, Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematol Oncol 2009;27(3):130-9
   PubMed Web of Science ®Google Scholar
• Wu C, Jiang J, Shi L, Xu N. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28(6B):3997-4002
   PubMed Web of Science ®Google Scholar
• Hui D, Qiang L, Jian W, A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009;41(1):36-41
   PubMedGoogle Scholar
• Jiang JT, Shen YP, Wu CP, Increasing the frequency of CIK cells adoptive immunotherapy may decrease risk of death in gastric cancer patients. World J Gastroenterol 2010;16(48):6155-62
   PubMed Web of Science ®Google Scholar
• Weng DS, Zhou J, Zhou QM, Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008;31(1):63-71
   PubMed Web of Science ®Google Scholar
• Shi M, Zhang B, Tang ZR, Autologous cytokine-induced killer cell therapy in clinical trial phase I is safe in patients with primary hepatocellular carcinoma. World J Gastroenterol 2004;10(8):1146-51
   PubMed Web of Science ®Google Scholar
• Niu Q, Wang W, Li Y, Cord blood-derived cytokine-induced killer cells biotherapy combined with second-line chemotherapy in the treatment of advanced solid malignancies. Int Immunopharmacol 2011;11(4):449-56
   PubMed Web of Science ®Google Scholar
• Jiang J, Xu N, Wu C, Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res 2006;26(3B):2237-42
   PubMed Web of Science ®Google Scholar
• Li H, Wang C, Yu J, Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009;11(8):1076-83
   PubMed Web of Science ®Google Scholar
• Liu L, Zhang W, Qi X, randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clin Cancer Res 2012;18(6):1751-9
   PubMed Web of Science ®Google Scholar
• Hontscha C, Borck Y, Zhou H, Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137(2):305-10
   PubMed Web of Science ®Google Scholar
• Verneris MR, Arshi A, Edinger M, Low levels of Her2/neu expressed by Ewing's family tumor cell lines can redirect cytokine-induced killer cells. Clin Cancer Res 2005;11(12):4561-70
   PubMed Web of Science ®Google Scholar
• Kornacker M, Verneris M, Kornacker B, The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab. Cytotherapy 2006;8(1):13-23
   PubMed Web of Science ®Google Scholar
• Marin V, Kakuda H, Dander E, Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal. Exp Hematol 2007;35(9):1388-97
   PubMed Web of Science ®Google Scholar
• Elia A, Inghirami G, Circosta PC, Retargeting of Citokine-Induced Killer (CIK) Cells with Molecularly Engrafted T-Cell Receptors (TCR): a preclinical in vitro and in vivo study. American Society of Hematology; 2011; San Diego, CA, USA. Blood (ASH Annual Meeting Abstracts) Nov 2011;118:1917
   Google Scholar
• Wolchok JD, Neyns B, Linette G, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010;11(2):155-64
   PubMed Web of Science ®Google Scholar
• Thompson JA, Hamid O, Minor D, Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial. J Immunother 2012;35(1):73-7
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Thanendrarajan S, Nowak M, Abken H, Schmidt-Wolf IG. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35(9):1136-42
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhang H, Li Y, Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res 2010;29:118
   PubMedGoogle Scholar
• Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010;2010:435745
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Yang JC, Sherry RM, Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011;17(13):4550-7
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985;313(23):1485-92
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316(15):889-97
   PubMed Web of Science ®Google Scholar
• Carnevale-Schianca F, Cignetti A, Capaldi A, Allogeneic nonmyeloablative hematopoietic cell transplantation in metastatic colon cancer: tumor-specific T-cells directed to a tumor-associated antigen are generated in vivo during GVHD. Blood 2006;107(9):3795-803
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N, Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343(11):750-8
   PubMed Web of Science ®Google Scholar